2022-12-20
GENIXCURE-ToolGen, Joint R&D contract for treatment of progeria
▲ Kim Young-ho, CEO of ToolGen (left), and Moon Hong-sung, CEO of GENIXCURE
ToolGen gene editing platform utilizes AAV technology from GENIXCURE
ToolGen announced on the 20th that it has signed a joint research and development agreement with ANL BIO to develop progeria gene therapy.
Yoon So-young, a bio-speculator